GN
GNFTF.US Genfit SA
- Market cap
- USD 472M
- P/E
- -
- P/B
- 3.02x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is GNFTF.US undervalued?
Graham numberThe Graham number of Genfit SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genfit SA fundamental analysis
No fundamental analysis for Genfit SA yet.
Genfit SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genfit SA
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, w…
Full company profileGenfit SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genfit SA annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 284K | 118K | 69.0K | 30.8M | 765K | 80.1M | 20.2M | 28.6M | 67.0M | 65.4M | 83.6M |
| Gross Profit | -1.70M | -2.11M | -1.79M | 30.7M | 563K | 79.9M | 19.9M | 28.2M | 66.7M | 14.5M | 75.4M |
| Operating Income | -34.2M | -56.7M | -69.5M | -57.8M | -82.9M | 31.8M | -27.3M | -26.6M | 3.28M | -58.9M | -48.4M |
| EBITDA | -33.3M | -55.5M | -67.7M | -49.1M | -73.0M | 34.9M | -25.8M | -22.2M | 8.35M | -8.04M | -44.7M |
| Net Income | -33.7M | -58.6M | -79.5M | -65.1M | -101M | 67.3M | -23.7M | -28.9M | 1.51M | -85.9M | -104M |
| EPS | -1.25 | -1.88 | -2.55 | -1.76 | -2.60 | 1.21 | -0.48 | -0.58 | 0.03 | -1.72 | -2.06 |
| Balance Sheet | |||||||||||
| Total Assets | 166M | 293M | 229M | 310M | 199M | 282M | 216M | 174M | 151M | 158M | 153M |
| Total Liabilities | 23.4M | 189M | 209M | 226M | 215M | 163M | 121M | 106M | 82.2M | 182M | 202M |
| Shareholders' Equity | 143M | 104M | 20.9M | 84.1M | -16.2M | 119M | 94.5M | 68.0M | 69.2M | -23.6M | -48.5M |
| Cash & Short-term Investments | 152M | 274M | 207M | 277M | 171M | 259M | 141M | 77.8M | 81.8M | 101M | 114M |
| Total Debt | 6.25M | 164M | 170M | 184M | 186M | 74.2M | 75.3M | 70.2M | 62.1M | 151M | 179M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -27.2M | -49.9M | -56.1M | -47.7M | -96.4M | 99.9M | -72.6M | -55.4M | 15.5M | -25.3M | 13.3M |
| Capital Expenditure | 2.04M | 2.80M | 2.94M | 2.03M | 900K | 537K | 0.00 | 2.49M | 979K | 1.39M | 2.13M |
| Free Cash Flow | -29.3M | -52.7M | -59.0M | -49.7M | -97.3M | 99.4M | -72.6M | -57.9M | 14.2M | -26.7M | 11.2M |
| Ratios | |||||||||||
| ROE | -23.6% | -56.2% | -379.8% | -77.5% | - | 56.5% | -25.1% | -42.5% | 2.2% | - | - |
| ROA | -20.3% | -20.0% | -34.7% | -21.0% | -51.0% | 23.9% | -11.0% | -16.6% | 1.0% | -54.4% | -67.6% |
| Net Profit Margin | -11,854.6% | -49,664.4% | -115,247.8% | -211.2% | -13,231.5% | 84.0% | -117.5% | -101.2% | 2.2% | -131.4% | -124.0% |
| Debt to Equity | 0.04x | 1.57x | 8.10x | 2.18x | - | 0.62x | 0.80x | 1.03x | 0.90x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genfit SA dividends
Genfit SA has not paid dividends in the last 9 fiscal years.
Last stock split: 1009:1000 on Jan 9, 2014.
Who owns Genfit SA
- Insiders 13.22%
- Institutions 14.06%
- Public & others 72.72%
- Shares outstanding 50.1M
- Free float 41.1M
Genfit SA company profile
- Company name
- Genfit SA
- Ticker
- GNFTF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 180
- Fiscal year end
- December
- Address
- Parc Eurasanté, Loos, France, 59120
- Phone
- 33 3 20 16 40 00
- Website
- genfit.com
About Genfit SA
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, which is in Phase 1b clinical trial for the treatment of cholangiocarcinoma; and G1090N/NTZ, which is in Phase 1 clinical trial for the treatment of acute-on-chronic liver failure continuum. In addition, the company is involved in the development of drugs in preclinical stage, including SRT-015, CLM-022, and EViv for the treatment of acute-on-chronic liver failure continuum; VS-02-HE for the treatment of hepatic encephalopathy; and VS-01-HAC (UCD/OA) for the treatment of hyperammonemic crises, urea cycle disorder, and organic acidemias. It has strategic partnerships with Ipsen for the development and commercialization of elafibranor; and Labcorp for the development and commercialization of NASHnext, a blood-based molecular diagnostic test, as well as TS-01, a diagnostic tool for blood ammonia levels. The company was incorporated in 1999 and is headquartered in Loos, France.
Genfit SA management
10- Mr. Jean-Francois MouneyCo-Founder & Chairman of the Board · born 1955
- Mr. M. Pascal PrigentChief Executive Officer · born 1968
- Mr. John BrozekExecutive VP of Data & Information Technology and Director · born 1977
- Prof. Bart StaelsCo-Founder & Chairman of the Scientific Advisory Board · born 1963
- Mr. Thomas BaetzChief Financial Officer · born 1974
- Mr. Pascal CaiseyDeputy CEO & COO · born 1968
- Ms. Sakina Sayah-JeanneChief Scientific Officer · born 1972
- Mr. Jean-Christophe MarcouxChief Corporate Affairs Officer, Head of Investor Relations & Head of ESG · born 1977
- Mr. Laurent LannooCorporate Secretary & Director of Legal Affairs · born 1970
- Ms. Stefanie Magner J.D.Chief Compliance Officer & Executive VP of International Legal Affairs · born 1981